UC study examines role of metabolites in disease treatment
Findings could result in first-of-its-kind treatments for an aortic aneurysm
Each year, about 200,000 people in the United States are diagnosed with a bulge in the lower part of the aorta, the main artery in the body, called an abdominal aortic aneurysm (AAA).
New research from the University of Cincinnati examines the role a particular metabolite plays in the development of AAA and could lead to the first treatment of the condition.
The research was published in the journal Circulation.
“We started the study by examining whether AAA patients themselves had an increase in trimethylamine N-oxide (TMAO). We examined an American and Swedish cohort with 354 human samples, and we compared those AAA patients to 1,775 control subjects,” says Phillip Owens, PhD, co-first author of the study along with Tyler Benson, PhD, both of the Division of Cardiovascular Health and Disease in the UC College of Medicine. “We started going into animal models after that, looking at what happens when we feed a high choline diet which leads to higher production of TMAO.”
Choline, found in a variety of foods with the richest sources being meat, fish, poultry, dairy and eggs, is processed into the organic compound TMAO when meat is digested by the bacteria in the gut.
The research found that in humans, TMAO levels were increased in AAA patients, but that doesn’t mean it is causing the disease state, according to Owens. To see if TMAO had an actual effect, researchers tried to replicate it in an animal model to manipulate the levels of TMAO and then block those in the subject to see whether TMAO increases were exacerbating the disease.
Kelsey Conrad/Photo/Provided
“We found that a high choline diet produces increased levels of AAA, and increased aneurysm rupture as well,” says Owens. “When we take that same model and inhibit the levels of TMAO using gut microbial inhibitors, inhibiting the conversion of the choline to the trimethylamine to the TMAO, we were able to reduce the levels of choline-induced AAA. It was in fact not the choline, but the choline-induced TMAO that led to an increase in aneurysm.”
Owens says the research came about as the result of interest expressed in the topic by former UC College of Medicine student Kelsey Conrad, PhD, who is a co-first author on the paper.
“It’s always one of my goals to try to get a project that interests the student, not just have them do something in my lab that I need to get done,” says Owens. “We created this project for that student then we filed a grant and found the funds. It’s not usually the way it goes.”
Conrad says she’s grateful to have worked with a mentor in Owens who supported her growth in a way that considered her past experiences and aligned with her professional goals.
“The potential for this work to radically change clinical care and improve patient outcomes in AAA is very exciting,” says Conrad who is now a faculty member at Smith College in Massachusetts. “Selectively targeting the gut microbes to prevent the progression of disease for this population would be a novel therapy for these patients who currently lack any pharmacological treatment options.”
Where I’m excited is if these inhibitors do make it to market, it’s potentially something in our arsenal that we can have for AAA where right now we have nothing.
Phillip Owens, PhD
There are an estimated 1 million men and women with AAAs in the United States and Owens says when you extrapolate that to the world population of 7 billion, that means potentially 20 to 30 million people worldwide have an AAA.
“We’ve gotten it to work in animal models which doesn’t necessarily mean it’s going to work in humans,” says Owens. “I think if the data has shown us one thing, it’s that TMAO is markedly increased in several cardiovascular diseases and if you inhibit it, at least in animal models, you do impact inflammation and overall mortality. Where I’m excited is if these inhibitors do make it to market, it’s potentially something in our arsenal that we can have for AAA where right now we have nothing.”
That may be a possibility sooner than later, Owens adds. Stanley Hazen at the Cleveland Clinic and co-author on the study, developed the drug fluoromethyl choline used in the studies and is constantly working on refining these inhibitors, which are currently being evaluated for their efficacy to inhibit TMAO in humans.
Lead photo at top of Phillip Owens/Andrew Higley/UC Marketing + Brand
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
UC joins national study on stroke prevention using wearables
November 7, 2022
The University of Cincinnati is part of a multimillion-dollar grant from the National Heart, Lung, and Blood Institute to study a strategy to prevent stroke in patients with atrial fibrillation. The trial will incorporate the use of an app on Apple Watch to monitor an irregular heartbeat to reduce patients’ reliance on blood-thinning medication.
UC study examines role of metabolites in disease treatment
June 8, 2023
Each year, about 200,000 people in the United States are diagnosed with a bulge in the lower part of the aorta, the main artery in the body, called an abdominal aortic aneurysm (AAA). New research from the University of Cincinnati examines the role a particular metabolite plays in the development of AAA and could lead to the first treatment of the condition.
UC study focus: Faster, more accurate way to diagnose lung infections
August 14, 2023
A federally funded study, led by University of Cincinnati researcher Nalinikanth Kotagiri, looks to develop a new imaging method that can identify certain types of lung infections — in real time — in order to speed up treatment for critically ill patients.
Fight or flight response may hinge on protein in skeletal muscular system
April 22, 2021
Taejeong Song, PhD, a postdoctoral fellow in the UC College of Medicine, says a regulatory protein found in skeletal muscle fiber may play an important role in the body’s fight or flight response when encountering dangerous situations.
UC cardiologist finds proteins in diabetic patients may indicate future heart disease
May 13, 2021
Donald Lynch Jr., MD, assistant professor at the University of Cincinnati College of Medicine, will be presenting preliminary research at the American College of Cardiology on Saturday, May 15, that suggests plasma proteins discovered in the blood samples of diabetic patients who went on to develop obstructive coronary disease (OCAD) may serve as biomarkers of severe heart blockage.
Medscape/Reuters Health: Long-Term Complications from Subcutaneous ICDs Assessed
August 5, 2021
Reuters Health spoke with Alexandru Costea, MD, professor in the UC College of Medicine, about a study on implantable cardioverter defibrillators.
COVID-19 continues to rage, but so does cardiovascular disease
January 27, 2021
UC cardiologists are hoping to call attention to the dangers still posed by heart disease during February, which is American Heart Month. The first Friday of the month is designated National Wear Red Day by Go Red for Women and the American Heart Association to call attention to the risk heart disease presents for women. Heart disease has traditionally been the top killer of American women and men.
Fox 19: Taking care of your heart
February 1, 2021
University of Cincinnati cardiologist Richard Becker, MD, says heart disease remains the leading killer of American women and men even though the COVID-19 pandemic was responsible for a spike in deaths during periods of 2020. Dr. Becker reminds residents during American Heart Month to practice good heart health.
Researcher develops app to reach Black community with COVID-19 information
October 29, 2020
Donald Lynch, MD, a University of Cincinnati cardiologist, is partnering with researchers in St. Louis and rural Georgia to develop a smartphone app that will deliver COVID-19 information and education that is targeted toward Black communities.
Everyday Health: Does chest pain always mean a heart attack?
November 28, 2022
The American Heart Association (AHA) says that chest pain accounts for more than 6.5 million emergency room visits each year in the United States, plus nearly 4 million outpatient visits. While not all episodes of chest discomfort turn out to be life-threatening, chest pain is the most common symptom of a heart attack in adults of all ages, so it needs to be taken seriously. In a story posted by Everyday Health, Richard Becker, MD, of the UC College of Medicine is one of the experts quoted.